CN112004801A - 一种c-MET 抑制剂的晶型及其盐型和制备方法 - Google Patents

一种c-MET 抑制剂的晶型及其盐型和制备方法 Download PDF

Info

Publication number
CN112004801A
CN112004801A CN201980027588.0A CN201980027588A CN112004801A CN 112004801 A CN112004801 A CN 112004801A CN 201980027588 A CN201980027588 A CN 201980027588A CN 112004801 A CN112004801 A CN 112004801A
Authority
CN
China
Prior art keywords
degrees
compound
formula
ray powder
angles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980027588.0A
Other languages
English (en)
Other versions
CN112004801B (zh
Inventor
徐雄彬
李刚
姚婷
王坤
胡利红
丁照中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujian Guangsheng Zhonglin Biotechnology Co ltd
Original Assignee
Fujian Cosunter Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujian Cosunter Pharmaceutical Co Ltd filed Critical Fujian Cosunter Pharmaceutical Co Ltd
Publication of CN112004801A publication Critical patent/CN112004801A/zh
Application granted granted Critical
Publication of CN112004801B publication Critical patent/CN112004801B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明公开了一种c‑MET抑制剂的晶型及其盐型和制备方法，具体涉及式(I)所示化合物及其盐型、晶型，还包括所述晶型和盐型在制备治疗肿瘤药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN201980027588.0A 2018-04-26 2019-04-26 一种c-MET抑制剂的晶型及其盐型和制备方法 Active CN112004801B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018103876932 2018-04-26
CN201810387693 2018-04-26
PCT/CN2019/084515 WO2019206268A1 (zh) 2018-04-26 2019-04-26 一种c-MET抑制剂的晶型及其盐型和制备方法

Publications (2)

Publication Number Publication Date
CN112004801A true CN112004801A (zh) 2020-11-27
CN112004801B CN112004801B (zh) 2023-09-08

Family

ID=68294814

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980027588.0A Active CN112004801B (zh) 2018-04-26 2019-04-26 一种c-MET抑制剂的晶型及其盐型和制备方法

Country Status (13)

Country Link
US (1) US11465986B2 (zh)
EP (1) EP3786155B1 (zh)
JP (1) JP7118349B2 (zh)
KR (1) KR102374933B1 (zh)
CN (1) CN112004801B (zh)
AU (1) AU2019260240B2 (zh)
CA (1) CA3098336C (zh)
EA (1) EA039713B1 (zh)
ES (1) ES2962679T3 (zh)
IL (1) IL278281B1 (zh)
TW (1) TWI768205B (zh)
WO (1) WO2019206268A1 (zh)
ZA (1) ZA202007037B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566913B (zh) * 2018-08-23 2022-05-27 福建广生中霖生物科技有限公司 三并环类化合物的晶型及其应用
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1930126A (zh) * 2004-03-05 2007-03-14 万有制药株式会社 吡啶酮衍生物
CN101687857A (zh) * 2007-07-12 2010-03-31 默克专利有限公司 嘧啶基哒嗪酮衍生物
CN104144925A (zh) * 2011-10-17 2014-11-12 拜耳知识产权有限责任公司 作为hif抑制剂的取代的噁二唑基吡啶酮和噁二唑基哒嗪酮
CN109311812A (zh) * 2016-10-27 2019-02-05 福建广生堂药业股份有限公司 作为c-MET抑制剂的吡啶酮类化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008062826A1 (de) 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
EA019342B1 (ru) * 2009-01-08 2014-02-28 Мерк Патент Гмбх Новые полиморфные формы гидрохлоридной соли 3-(1-{3-[5-(1-метилпиперидин-4-илметокси)пиримидин-2-ил]бензил}-6-оксо-1,6-дигидропиридазин-3-ил)бензонитрила и способы их получения

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1930126A (zh) * 2004-03-05 2007-03-14 万有制药株式会社 吡啶酮衍生物
CN101687857A (zh) * 2007-07-12 2010-03-31 默克专利有限公司 嘧啶基哒嗪酮衍生物
CN101743241A (zh) * 2007-07-12 2010-06-16 默克专利有限公司 哒嗪酮衍生物
CN104144925A (zh) * 2011-10-17 2014-11-12 拜耳知识产权有限责任公司 作为hif抑制剂的取代的噁二唑基吡啶酮和噁二唑基哒嗪酮
CN109311812A (zh) * 2016-10-27 2019-02-05 福建广生堂药业股份有限公司 作为c-MET抑制剂的吡啶酮类化合物

Also Published As

Publication number Publication date
KR20210005142A (ko) 2021-01-13
JP7118349B2 (ja) 2022-08-16
CA3098336A1 (en) 2019-10-31
EP3786155A1 (en) 2021-03-03
ZA202007037B (en) 2021-10-27
AU2019260240A1 (en) 2020-12-17
IL278281A (zh) 2020-12-31
EP3786155B1 (en) 2023-08-16
US11465986B2 (en) 2022-10-11
ES2962679T3 (es) 2024-03-20
AU2019260240B2 (en) 2023-05-11
TWI768205B (zh) 2022-06-21
EA039713B1 (ru) 2022-03-03
JP2021522265A (ja) 2021-08-30
EP3786155A4 (en) 2021-05-19
CA3098336C (en) 2024-03-19
US20210238163A1 (en) 2021-08-05
TW201945359A (zh) 2019-12-01
KR102374933B1 (ko) 2022-03-15
IL278281B1 (en) 2024-09-01
WO2019206268A1 (zh) 2019-10-31
EA202092558A1 (ru) 2021-02-24
CN112004801B (zh) 2023-09-08

Similar Documents

Publication Publication Date Title
RU2645672C2 (ru) Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ
IL266126A (en) Pyridone compound as a c – met inhibitor
CN112004801B (zh) 一种c-MET抑制剂的晶型及其盐型和制备方法
WO2022022687A1 (zh) 含嘧啶基团的三并环类化合物的盐型、晶型及其制备方法
CN111886228B (zh) 一种c-MET/AXL抑制剂的晶型
CN116133662A (zh) 氮杂环丁烷取代化合物的晶型
WO2020238802A1 (zh) 一种c-MET/AXL抑制剂的晶型
WO2023093859A1 (zh) Axl激酶抑制剂的盐、其制备方法和用途
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
WO2022135580A1 (zh) 吡啶并吡咯类化合物的晶型、制备方法及其应用
CN113784971A (zh) 一种egfr抑制剂的晶型及其制备方法
WO2021190623A1 (zh) Fgfr4抑制剂的盐型、晶型及其用途
WO2024094016A1 (zh) 一种二噁烷并喹啉类化合物的盐、其晶型以及它们的制备方法及应用
CN113227073B (zh) Egfr酪氨酸激酶的选择性抑制剂的盐及其晶型
Wang et al. Design, synthesis, and evaluation of antitumor activity of quinazoline derivatives containing different terminal segments of basic amine groups
CN116655599A (zh) 一类egfr别构抑制剂的合成及其用途
CN114945576A (zh) 氘代噻吩并吡啶类化合物
CN110234649A (zh) Fgfr4抑制剂的盐、晶体、制备方法及其用途
NZ753020B2 (en) Pyridone compound as c-met inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220511

Address after: 355300 building 1-7, Fuyuan Industrial Park, Zherong County, Ningde City, Fujian Province

Applicant after: Fujian Guangsheng Zhonglin Biotechnology Co.,Ltd.

Address before: 355300 Fuyuan Industrial Zone, Dongyuan Township, Zherong County, Ningde City, Fujian Province

Applicant before: FUJIAN COSUNTER PHARMACEUTICAL Co.,Ltd.

GR01 Patent grant
GR01 Patent grant